Cancer Drug Encyclopedia
Approved oncology medications — what they treat, how they work and key safety information.
Multiple myeloma in combination with dexamethasone; maintenance therapy following autologous stem cell transplant; transfusion-dependent anemia due to myelodysplastic syndromes; relapsed mantle cell lymphoma; and follicular lymphoma.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.
Approved for use in oncology care according to FDA-approved indications.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
HR-positive, HER2-negative advanced, metastatic, or high-risk early Breast Cancer.
HR-positive, HER2-negative advanced, metastatic, or high-risk early Breast Cancer.
Advanced solid tumors and hematologic malignancies with matching genomic alterations.
Non-Hodgkin lymphoma (diffuse large B-cell, follicular), chronic lymphocytic leukemia in combination with fludarabine and cyclophosphamide, and granulomatosis with polyangiitis.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.